February 10, 2017 / 1:22 PM / 8 months ago

EMA panel recommends that use of Actelion's Uptravi may continue

Swiss biotech company Actelion's logo is seen on a package of Uptravi medications displayed at the company's headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion’s Uptravi drug may continue to be used in line with current prescription information amid a probe into five deaths in France among those using the pulmonary arterial hypertension medicine.

Reporting by John Miller; Editing by Michael Shields

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below